Clinical trials: Cardiotoxicity
Cancer, Cardiotoxicity
Role of Aerobic Exercise to Modulate Cardiotoxicity in Long Term Cancer Survivors Exposed to Anthracycline Therapy
Over 50% of the more than 270,000 childhood cancer survivors in the U.S. have been treated with anthracyclines and thus are at risk of developing cardiotoxicity.
- Trial name
- NCT04036032
- Testing
- Exercise program
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Connecticut Children's Medical Center
Cancer
Prevention of Anthracycline-induced Cardiotoxicity
Anthracycline based anti-tumoral therapies are know to develop cardiac damage that could also lead to heart failure. Monocentric studies proved that a treatment with ACE inhibitors (ACEi) and betablockers (BB) during the first…
- Trial name
- ICOS-ONE (NCT01968200)
- Testing
- Enalapril
- Where
- Italy
- Volunteers
- 268 people
- Sponsor
- European Institute of Oncology
Childhood Cancer
Cardiac 3D MRI in Pediatric Cancer Patients
This is a non-randomized prospective pilot study in a single academic center with historic controls. This study will compare Cardiac Magnetic Resonance Images (MRI) of patients who have undergone childhood cancer treatment that…
- Trial name
- NCT02130934
- Testing
- Cardiac 3D MRI
- Where
- 2 sites in United States
- Sponsor
- Majd Makhoul
Cardiotoxicity, Chemotherapeutic Toxicity
Prevention of Chemotherapy-induced Cardiotoxicity in High-risk Patients
In cancer patients, the increase of troponin I soon after chemotherapy is a strong predictor of left ventricular dysfunction and poor cardiologic outcome.
- Trial name
- NCT00292526
- Testing
- Enalapril
- Where
- Italy
- Volunteers
- 114 people
- Sponsor
- European Institute of Oncology
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Biomarkers to Predict Cancer Therapy-related Cardiotoxicity
This study evaluates why some cancer patients but not others experience changes in heart function following treatment with chemotherapy.
- Trial name
- NCT06353191
- Testing
- Non-Interventional Study
- Where
- 4 sites in United States
- Volunteers
- 693 people
- Sponsor
- Mayo Clinic
Lymphoma, Non-Hodgkin, Hodgkin Lymphoma
Subclinical Cardio-toxicities Evaluation With Strain Rate Echocardiography After Chemotherapy and/or Mediastinal Radiotherapy in Patient With Lymphoma
Treatments-related cardiotoxicity is a critical issue in long term lymphoma survivors, particularly at young age, and its early identification is important to prevent clinically relevant cardiac events.
- Conditions
- Lymphoma, Non-Hodgkin, Hodgkin Lymphoma, Toxicity, Cardiac
- Trial name
- Cardiocare (NCT03480087)
- Where
- Italy
- Volunteers
- 118 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Multiple Myeloma, Shortness of Breath
Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib
This study will explore why some multiple myeloma patients who receive carfilzomib (an anti-cancer medication) experience shortness of breath while others do not.
- Conditions
- Multiple Myeloma, Shortness of Breath, Dyspnea, Cardiotoxicity
- Trial name
- NCT04827563
- Testing
- EndoPAT, Blood Pressure Cuff, Echocardiogram
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Chicago
Heart Failure, Anthracycline-induced Cardiac Toxicity
Use of Dapagliflozin in Primary Prevention of Cardiotoxicity of Anthracycline Chemotherapy in Breast Cancer Patients
The goal of this randomized, double-blind, placebo-controlled clinical trial is to determine whether dapagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, can help prevent anthracycline-induced cardiotoxicity caused…
- Conditions
- Heart Failure, Anthracycline-induced Cardiac Toxicity, Endothelial Function (FMD), Arterial Stiffness
- Trial name
- Alpaca (NCT07245069)
- Testing
- Dapagliflozin 10 mg
- Where
- Slovenia
- Volunteers
- 100 people
- Sponsor
- University Medical Centre Ljubljana
Cardio-oncology, Hematopoietic Stem Cell Transplantation
Early Identification and Evaluation of Cyclophosphamide Cardiotoxicity
Hematopoietic stem cell transplantation is an important method for the treatment of hematological diseases and cyclophosphamide is a commonly used chemotherapeutic agent for transplant pretreatment.
- Conditions
- Cardio-oncology, Hematopoietic Stem Cell Transplantation, Cardiotoxicity, Cyclophosphamide
- Trial name
- EIECC (NCT05150080)
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Kai Mu
Cardiomyopathies, Chemotherapy Effect
Bisoprolol Administration to Prevent Anthracycline-induced Cardiotoxicity
Anthracyclines are one of the most well-known and effective drugs used to treat malignancies.The most important limiting factor in the use of this drug is its cardiac toxicity which includes cardiomyopathy and congestive heart…
- Conditions
- Cardiomyopathies, Chemotherapy Effect, Diastolic Dysfunction, Systolic Dysfunction
- Trial name
- NCT05175066
- Testing
- Bisoprolol
- Where
- Iran
- Volunteers
- 80 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Breast Cancer, Peripheral Neuropathy
Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients
Aim of the work This study aims to evaluate the possible beneficial role of silymarin in attenuating both doxorubicin related cardiac and hepatic toxicities and paclitaxel associated peripheral neuropathy and improving cognitive…
- Conditions
- Breast Cancer, Peripheral Neuropathy, Cardiac Toxicities, Hepatic Toxicity
- Trial name
- NCT05595109
- Testing
- Silymarin
- Where
- Egypt
- Volunteers
- 56 people
- Sponsor
- Tanta University
Cardiac Affections
Comparison of Cardiotoxicity Induced by Selective Estrogen REceptor Modulators and aNti-Aromatase
Selective estrogen receptor modulators and aromatase inhibitors for the treatment of breast cancer seems to have an impact on the cardio-vascular system.
- Trial name
- SERENA (NCT03259711)
- Testing
- Hormonal therapies L02 in the ATC classification
- Where
- France
- Volunteers
- 20,000 people
- Sponsor
- Groupe Hospitalier Pitie-Salpetriere
Breast Cancer Stage 2 and 3
Evaluation of Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients
This study aims at evaluating the possible safety and efficacy of fenofibrate in attenuating doxorubicin related cardiac toxicity in breast cancer patients.
- Trial name
- NCT06155331
- Testing
- Fenofibrate, Doxorubicin, Cyclophosphamide
- Where
- Egypt
- Volunteers
- 44 people
- Sponsor
- Tanta University
Artificial Intelligent, Cardiotoxicity
Smart Home Care of Cloud Base ECG on the Cardiotoxicity Prevention on the Cancer Patients.
Thoracic malignancy is the most commonly diagnosed cancer worldwide.1,2 The incidence of thoracic malignancy has decreased in North America, but not in Asia, where it continues to show an increasing trend.
- Conditions
- Artificial Intelligent, Cardiotoxicity, Cardiac Monitor, Cancer Treatment
- Trial name
- AI (NCT04885088)
- Testing
- Wisdom bracelet
- Volunteers
- 400 people
- Sponsor
- Ju-Chi Liu
Colorectal Adenocarcinoma, Oesogastric
Cardiovascular Events From Trifluridine/Tipiracil +/- Oxaliplatin in Colorectal/Oesogastric Adenocarcinoma Patients
The purpose of this study is to assess the incidence of cardiovascular events in patients with esophageal/stomach or colorectal cancer treated by trifluridine/tipiracil +/- oxaliplatin after an episode of cardiac angina-related…
- Trial name
- NCT04894123
- Testing
- Trifluridine/Tipiracil, Oxaliplatin
- Where
- 11 sites in France
- Volunteers
- 1 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Heart Failure
Ability of L-carnitine to Prevent Heart Damage in Breast Cancer Patients Receiving Anthracycline Chemotherapy
Breast cancer is very common and afflicts 1 in 9 North American women. The treatment of breast cancer often requires the use of chemotherapy including "anthracyclines".
- Trial name
- NCT00247975
- Testing
- L-carnitine
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Non-small Cell Lung Cancer, Radiation Toxicity
Radiation-induced Cardiac Toxicity After Non-small Cell Lung Cancer Radiotherapy
Despite the growing interest in investigating how the radiotherapy (RT) dose to anatomical substructures of the heart links to survival, the heart substructures at risk remain poorly defined.
- Conditions
- Non-small Cell Lung Cancer, Radiation Toxicity, Cardiac Toxicity
- Trial name
- NCT04867564
- Testing
- Echocardiography
- Where
- Poland
- Volunteers
- 100 people
- Sponsor
- Military Institute od Medicine National Research Institute
Breast Cancer, Cardiac Toxicity
Side Effects Involving the Heart in Women With Breast Cancer Receiving Doxorubicin and Trastuzumab
RATIONALE: Studying samples of blood and tissue in the laboratory from women receiving doxorubicin and trastuzumab for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers for…
- Conditions
- Breast Cancer, Cardiac Toxicity, Cardiovascular Complications
- Trial name
- PACE in BC (NCT00875238)
- Testing
- trastuzumab, doxorubicin hydrochloride, polymorphism analysis
- Where
- 4 sites in United States
- Volunteers
- 133 people
- Sponsor
- Vanderbilt University
Cardiac Toxicity, Sarcoma
Combination Chemotherapy Before and After Surgery in Treating Patients With Osteosarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving chemotherapy before surgery may shrink the tumor so that it can be removed during surgery.
- Trial name
- NCT00019864
- Testing
- filgrastim, cisplatin, dexrazoxane hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- National Cancer Institute (NCI)
DLBCL - Diffuse Large B Cell Lymphoma
Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
Patients treated for DLBCL are at high risk of developing AICD. This adverse event is characterized by irreversible damage to the heart muscle with a loss of cardiomyocytes and subsequent decline in cardiac pumping capacity.
- Trial name
- HO170DLBCL (NCT06220032)
- Testing
- Dexrazoxane, Rituximab, Cyclophosphamide
- Where
- 25 sites in Netherlands
- Volunteers
- 324 people
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland